The Wovex bifurcated dacron vascular prostheses have been available on the French market since 2008. They are mainly used to treat aneurysmal or occlusive aortic diseases. To date, they have not been the subject of a specific clinical efficacy/safety study, unlike other Dacron prostheses used in the same field. We purpose a monocentric, retrospective, consecutive study based on medical data, including all the patients operated for aneurysms or occlusive disease of the abdominal aorta at Dijon Bourgogne University Hospital between 2013 and 2017 and who received a WOVEX bifurcated prosthesis (Wovex® Polyester Vascular Protheses). The objective is to explore the safety (short-term postoperative morbidity and mortality at 5 years) and efficacy (primary permeability, secondary permeability and dilatation of the prosthesis at 5 years) of the WOVEX prosthesis.
Study Type
OBSERVATIONAL
Enrollment
173
demographics co-morbidities risk factors operative, hospital and vascular follow-up data
Chu Dijon Bourogne
Dijon, France
Safety and security
Occurrence of death or major re-intervention (bypass stenosis/thrombosis, false anastomotic aneurysm, prosthesis infection, anastomosis rupture, amputation) over the entire follow-up period (from date of surgery to study end date (February 28, 2021))
Time frame: 5 years
Major surgical reintervention
bypass stenosis/thrombosis, false anastomotic aneurysm, prosthesis infection, anastomosis rupture, amputation throughout the follow-up period
Time frame: 5 years
Primary permeability
Stenosis/thrombosis of the prosthesis over the entire follow-up period
Time frame: 5 years
Secondary permeability
Stenosis/thrombosis after reintervention over the entire follow-up period
Time frame: 5 years
Dilatation of the prothesis
Diameter of the prosthesis over the entire follow-up period
Time frame: 5 years
Occurence of MAVE and MACE
Occurence of MAVE and MACCE (re-interventions, ischemic cardiac, neurological (stroke/TIA), pulmonary and renal complications) throughout the follow-up period
Time frame: 5 years
Occurence of adverse events
Other adverse events over the entire follox-up period
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.